Healthineers Puts Four New Supervisor Names Forward as Diagnostics Unit Prepares to Stand Alone

Siemens Healthineers used the run-up to its annual shareholder meeting to sketch out two very different kinds of change: a fresh supervisory board slate and the slow unshackling of its diagnostics arm.

The company said Wednesday that its supervisory board will nominate Melanie Kreis, Heyo Kroemer, Jonathan Lewin and Pascale Witz as new members at the 2027 annual general meeting. Roland Busch intends to step down early. The mandates of Veronika Bienert, Marion Helmes and Karl-Heinz Streibich expire at that same 2027 meeting, while Ralf Thomas and Peter Körte are to be put forward for re-election.

Diagnostics carve-out gathers pace

Separately, the group is pushing ahead with a separation of its in-vitro diagnostics business, which it wants to make organisationally independent by mid-2028 and which will gradually take the name Olyrian Diagnostics. During the transition the unit stays part of Siemens Healthineers, the company said. Reuters reported Thursday that Healthineers wants to sell the division, and chief executive Bernd Montag said interested parties have already come forward. The carve-out set in motion on Thursday is officially described as preparation for a standalone organisation.

Finance chief Jochen Schmitz told an analyst conference that the diagnostics unit will deliver an additional €400 million in savings, according to media reports.

A mixed final quarter

The separation plans landed alongside full-year figures published Thursday. For fiscal 2026, Siemens Healthineers posted comparable revenue growth of 4.0% and an adjusted EBIT margin of 16.2%, with adjusted unadjusted earnings per share of €2.42 for the year. In the fourth quarter, comparable revenue growth reached 5.9% and the adjusted EBIT margin came in at 15.9%, producing adjusted earnings per share of €0.69 for the period.

Deutsche Bank Research kept its "Hold" rating on the stock on Friday following the numbers, with a price target of €39. Analyst Falko Friedrichs called the fourth quarter mixed, pointing in particular to Precision Therapy.

Roadshow circuit gets under way

Investor outreach is running in parallel. Healthineers holds a roadshow with JP Morgan in London today, following Thursday's annual results. On 10 November 2026 the company continues its investor conversations with a UBS roadshow in Frankfurt; the same day brings a JP Morgan roadshow in Paris and participation in the UBS European Healthcare Conference in London.

The next scheduled financial date is publication of the fiscal 2026 annual report on 25 November, with a virtual Bank of America CEO call set for 10 December.